Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493512 · ClinicalTrials.gov registry record · Phase 1
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07493512: Recruiting Phase 1 study, sponsored by Amgen.
NCT07493512 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07493512, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Primary Outcome
This will include treatment-emergent adverse events, serious adverse events, treatment-related adverse events, and fatal adverse events.
Interventions
- DRUG Xaluritamig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-28 |
| Est. Completion | 2030-07-30 |
| Phase | Phase 1 |
What NCT07493512 shows while recruiting
NCT07493512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 1 intervention - of which Xaluritamig is the first listed.
NCT07493512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07493512 about?
NCT07493512 is a clinical study titled "Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer". The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT07493512?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-04-28. Estimated completion is 2030-07-30.
What interventions are being tested in trial NCT07493512?
The interventions under investigation include: Xaluritamig (DRUG).
Who is sponsoring clinical trial NCT07493512?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07493512's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI